Form 4: Supernus Pharmaceuticals Executive Reports Stock Transactions
SEC Form 4 Filing
Padmanabh P. Bhatt, a Senior VP at Supernus Pharmaceuticals, reports the acquisition and disposal of company stock related to performance share units.
Summary
- On August 20, 2024, Padmanabh P. Bhatt, Sr. VP of IP and CSO at Supernus Pharmaceuticals, reported transactions involving the company's common stock.
- Bhatt acquired 1,250 shares of common stock upon the settlement of performance share units granted on February 23, 2023.
- Simultaneously, 572 shares were withheld by the company to satisfy tax obligations related to the vesting of these units.
- Following these transactions, Bhatt directly owns 9,679 shares of Supernus Pharmaceuticals stock.
Sentiment
Score: 5
Explanation: This is a neutral report on stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies. It provides transparency into the transactions of company insiders.
Stakeholder Impact
- Shareholders gain insight into executive compensation and stock ownership.
- The transactions have a minor impact on the overall share structure of the company.
Key Dates
| Date | Description |
|---|---|
| February 23, 2023 | Reporting Person was awarded Performance Share Units |
| August 20, 2024 | Shares of common stock received upon the settlement of certain Performance Share Units |
| August 20, 2024 | Shares of common stock withheld by the Company to satisfy tax withholding requirements |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.